Sitagliptin is a DPP-4 inhibitor that increases endogenous incretins (GLP-1 and GIP), stimulating glucose-dependent insulin secretion.
Also known as: Januvia
No documented drug–drug interactions for this medicine.
Sitagliptin can be taken with or without food.
Take with or without food, at the same time.
EMC-UK — Januvia (sitagliptin) SmPC 4.2.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Inhibits DPP-4, increasing GLP-1 and GIP levels. Stimulates glucose-dependent insulin secretion and suppresses glucagon secretion.
Blocks DPP-4, preventing degradation of incretins GLP-1 and GIP. Elevated incretin levels stimulate insulin secretion only when glucose is elevated.
Oral bioavailability: 87%. Food does not affect absorption. Tmax: 1-4 hours.
Minimally metabolised (~16% via CYP3A4 with CYP2C8 contribution). ~79% excreted unchanged in urine. Low interaction potential.
~12.4 hours. Elimination: ~79% urine (unchanged), ~14% faeces.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
